Yunnan Baiyao Group Reports Improved Valuation Amid Strong Financial Performance

Yunnan Baiyao Group Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The company has reported a valuation score that reflects a shift in its financial metrics, indicating a more favorable assessment of its market position. Key financial indicators reveal a P/E ratio of 19, alongside a Price to Book Value of 2.42. The company’s EV to EBIT stands at 17.62, while the EV to EBITDA is recorded at 16.36. Additionally, Yunnan Baiyao showcases a PEG ratio of 1.27, which suggests a balanced growth perspective relative to its earnings. The dividend yield is notably attractive at 4.43%, providing a steady return for stakeholders. In terms of operational performance, the company has demonstrated resilience with a return on equity (ROE) of 12.59% and a return on capital employed (ROCE) of 17.64%. The latest quarter ending in March 2025 has shown positive financial results, particularly with operating cash flow reaching its highest at CNY 4,888.72 million. Furthermore, a reduction in raw material costs by 7.16% year-over-year has contributed to a more robust financial outlook. For more insights into Yunnan Baiyao Group Co., Ltd.'s financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.